Retinoic Acid Combined with Vitamin A Synergizes to Increase Retinyl Ester Storage in the Lungs of Newborn and Dexamethasone-Treated Neonatal Rats

A. Catharine Ross\textsuperscript{a}  Namasivayam Ambalavanan\textsuperscript{b}

\textsuperscript{a}Department of Nutritional Sciences and Huck Institute for Life Sciences, Pennsylvania State University, University Park, Pa., and \textsuperscript{b}Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Ala., USA

**Key Words**
Lung maturation • Glucocorticoids • Lung morphometry • Vitamin A status • Retinyl ester storage, liver • Retinoic acid

**Abstract**

*Background:* Retinyl esters (REs), the major storage form of vitamin A (retinol), provide substrates for the production of bioactive retinoids, including retinoic acid (RA), which are known to promote lung development and maturation. We previously showed that the nutrient-metabolite combination VARA (molar ratio 10 vitamin A to 1 RA), synergistically increased REs in the lungs of 1-week-old rats, compared to vitamin A or RA alone. **Objectives:** To test the hypotheses, first, that VARA is more effective in increasing lung RE than is vitamin A in newborn rats prior to alveolarization, and, second, that the effect of VARA is maintained during concurrent treatment with the glucocorticoid, dexamethasone (Dex). **Methods:** Newborn rats were treated with VARA, vitamin A alone, or oil (C) on postnatal days (P) 1–3, and RE in the lungs was quantified on P4, and again on P8 to assess retention. Additionally, neonatal rats were treated on P5–7 with VARA with and without Dex, and the lung and liver REs were quantified on P8. **Results and Conclusions:** Lung RE was nearly 8-fold higher in VARA compared to vitamin A-treated rats on P4 (p < 0.01) and 2.5-fold higher on P8. In neonates co-treated with Dex and VARA on P5–7, the elevation in lung RE on P8 by VARA was not antagonized by Dex, although Dex reduced growth. Lung morphology and development were not significantly altered. The VARA combination may significantly increase lung RE content even during concurrent Dex therapy. Because lung retinoids are important for lung maturation and repair, increasing lung RE may possibly have clinical benefit.

**Introduction**

Bronchopulmonary dysplasia (BPD) is a common cause of morbidity and a risk factor for poor long-term outcome in extremely premature infants [1–3]. Several studies have shown that vitamin A can reduce the risk of BPD in premature infants [2, 4–7]. In animal models, vitamin A deficiency is associated with histopathological changes similar to those in BPD [8]. Conversely, retinol has been shown to promote elastin formation [9] and alveolar development [10]. A beneficial effect of vitamin A on lung maturation is plausible because the active metabolite and hormonal form of vitamin A, retinoic acid
(RA), is well known to be an important regulator of cell proliferation, cell differentiation, and cell-cell interactions in nearly all tissues [11, 12]. In the embryonic period, retinoids are essential for normal stromal cell-mesenchymal cell interactions and organogenesis [13–15], while in the postnatal period retinoids are important regulators of lung growth, alveolar septation, and elastin formation [9, 10, 14, 16–21].

Retinyl esters (REs), the major storage form of vitamin A in most tissues, are important for maintaining retinoid homeostasis because the retinol released by the hydrolysis of REs can be metabolized in several ways depending on the vitamin A status, resulting in the re-esterification of retinol, its release into plasma, or its conversion into retinal and RA, the two major functional metabolites of vitamin A [22, 23]. Reserves of vitamin A in the liver, as well as plasma retinol levels, are relatively low at birth and lower still in prematurely born infants [2, 5, 24–26]. In the rat, the concentration of RE in the lungs peaks around gestational day 18 (E18), then decreases progressively until the third postnatal day (P3) [27]. Although lung and liver REs were higher in the offspring of mothers supplemented with vitamin A during late pregnancy, the concentration of REs in the lungs still declined after birth [28].

In a previous study in neonatal rats, we showed that a nutrient-metabolite combination containing vitamin A and RA in a 10:1 molar ratio (VARA) was several times more effective than vitamin A alone in increasing the concentration of REs in the lungs, as determined in P5–P8 neonates given a daily oral dose of VARA or the same amounts of its individual components [29]. Interestingly, the synergistic effect of VARA on RE formation was selective for the lungs, as VARA and the same amount of vitamin A alone increased liver REs to the same extent. In a follow-up study, we found that a greater fraction of newly absorbed $^3$H-retinol was taken into the lungs of neonates when $^3$H-retinol was co-administered with VARA versus with vitamin A alone, showing that a small proportion of RA included with vitamin A can have a significant impact on the metabolism of retinol in the lungs.

It is possible that the ability of VARA to enhance retinol uptake and RE storage in the lungs depends on the stage of lung development, and/or that it could be modified by other agents given concurrently. At birth, the lungs of newborn rats and mice are still in the saccular stage. Lung RE content declines during the saccular stage [26], which occurs between 24 and 38 weeks’ gestation in humans and between E17.5 to P4 in mice [30]. Glucocorticoids continue to be used in neonates for the treatment of BPD despite knowledge of their adverse effects [31, 32]. Previous studies have shown that dexamethasone (Dex) may reduce the levels of retinoid-binding proteins [33] and receptors [34], which potentially could affect the metabolism of retinol and the formation of REs. Thus, in the present studies we have addressed two questions: (1) is VARA more effective than vitamin A alone in increasing the lung RE concentration in the period prior to the onset of alveolarization, and (2) does Dex antagonize the ability of VARA to promote RE storage in the lungs of neonates?

**Methods**

**Oral Doses**

Vitamin A, VARA and oil (control) were prepared for oral administration as described previously [29]. Briefly, all-trans-retinyl palmitate and all-trans-RA (Sigma-Aldrich, St. Louis, Mo., USA) were prepared in canola oil as 2 × concentrations, then mixed 1:1 (wt:wt) with each other to form the VARA dose, which had a molar ratio of about 10 vitamin A:1 RA (0.05 mmol retinyl palmitate and 0.005 mmol RA/g dose). As described previously [29], the dose of vitamin A for rats was similar, after adjustment for metabolic weight, to 50,000 IU of vitamin A (equal to 15 mg retinol) that has been administered to human infants [35, 36], while the dose of RA was similar to a dose that promoted lung septation in neonatal rats [37]. Pups received approximately 0.4 μl/g body weight. Each pup was weighed daily before dosing and the dose volume was adjusted. Retinoids were stored at 4°C in foil-wrapped vials. Dex (Sigma-Aldrich) was prepared as a 0.5 mg/ml stock solution in ethanol and diluted 1:2,000 with sterile saline before administration [38].

**Animals and Experimental Treatments**

Animal procedures were approved by the Institutional Animal Use and Care Committee of the Pennsylvania State University. Pregnant Sprague-Dawley rats were bred in our animal facility and fed a vitamin A-adequate purified diet [39]. Food and water were freely available. In the first study, the time of birth was monitored and rat pups less than 24 h old (day 1 = <24 h of birth) were randomized within 4 litters and treated on days P1, P2, and P3 with VARA or oil (control) only. VARA, vitamin A or oil was delivered directly into the neonate’s mouth with a small-tipped micropipette. Tissues were collected from half of the neonates on P4 and from the remaining half on P8, without intervening treatment. In the second experiment designed to test the effect of VARA during co-treatment with Dex, pups were randomly assigned within litters to receive oil (control); VARA, Dex only, and Dex plus VARA on P5, P6 and P7. The dose used provided a neonate weighing 12.5 g with approximately 130 μg of retinyl palmitate (72 μg or 0.25 μmol retinol) and 7.5 μg (0.025 μmol) of RA, in about 5 μl of oily suspension. Neonates assigned to Dex treatment received 0.25 μg Dex s.c. in 10 μl of sterile saline, injected by microsyringe under the skin just above the tail each day, as described earlier by Massaro and Massaro [38].

---

Lung Vitamin A in Dexamethasone-Treated Rats

Neonatology 2007;92:26–32
At the end of each experiment, neonates were euthanized one at a time using carbon dioxide inhalation and weighed, and blood was collected for separation of plasma by centrifugation. The lungs and liver were removed, blotted, weighed and snap-frozen in liquid nitrogen for storage at –80°C prior to retinoid analysis.

In order to determine changes in lung morphology, the experiment was repeated and the lungs of neonates treated with oil (control); VARA, Dex only, and Dex plus VARA on P5–P7 were perfused on P14 with phosphate-buffered 10% formalin at 20 cm water pressure [40], and lung morphometry was evaluated as described below.

**Lung Morphometry**

Lungs from experiment 2 (n = 4/group) were inflated and perfusion fixed with neutral phosphate-buffered 10% formalin [41]. 5-μm-thick sections were prepared from the base to apex of each lung, and sections were stained with hematoxylin and eosin. Six random fields were evaluated per slide for each variable as previously described [29] by an observer masked to slide identity. The software package MetaMorph (Universal Imaging Corporation, Downingtown, Pa., USA) interfaced with a Nikon Labophot microscope equipped with a QiCam Fast Cooled high resolution CCD camera (1,392 × 1,040 pixels = 4.15 MB TIF file per image) was used for image analysis. Epithelial injury and hemorrhage were assessed at a magnification of 400× using a scale of 0 (normal) to 5 (most), based on predefined definitions (e.g., a hemorrhage score of 1 corresponds to red blood cells (RBC) in seque while a score of 2 corresponds to scattered intra-alveolar RBC (modified from Simma et al. [42]). Tissue density and mean linear intercept [43] were assessed at 100×. Tissue density was the proportion of field occupied by tissue (area occupied by tissue/area occupied by lung tissue plus alveoli). The RAC, an indicator of the number of new generations of alveoli that develop between the bronchiole and the periphery of its acinus, was measured by the method of Cooney and Thurlbeck [44]. Briefly, an imaginary perpendicular line is drawn extending from a terminal bronchiole to the closest edge of the acinus, either the pleura or a lobular septum. The number of saccular wall intercepts between the origin and the pleura was the RAC. This was measured on six different 100× fields per slide, each slide consisting of a coronal section from apex to base of both lungs.

**Retinoid Analysis**

Plasma retinol was determined after saponification, and lung and liver REs and retinol were quantified after total lipid extraction and separation of retinol and REs by reverse-phase HPLC [29, 45] using trimethylmethoxyphenyl-retinol added as an internal standard for quantification. Unesterified retinol was typically <5% of RE in the lungs and <2% of RE in the liver, and was included as total RE + retinol/g tissue.

**Statistics**

Data are reported as the mean ± SEM. The results were analyzed by one-way ANOVA or Student’s t test when appropriate (SuperANOVA software, Abacus, Berkeley, Calif., USA). Data were subjected to log_{10} transformation prior to statistical analysis when group variances were unequal. Results with p < 0.05 were considered significant.

**Results**

**Retinoic Acid Combined with Vitamin A (VARA) Increases Lung RE in Newborns, which Persists after Treatment**

To determine whether the lungs of newborn rats respond to VARA, newborn rats <24 h old were treated daily for 3 days, beginning on P1, with VARA, vitamin A alone, or oil (normal control group). Lung RE was determined on P4 in half of the neonates, and on P8 in the remaining neonates. Lung RE on P4 was about 8 times higher in the VARA group than in the group that received an equal amount of vitamin A alone (fig. 1), while vitamin A alone increased lung RE about 3.4 times above the level in the control group on P4. After cessation of treatment, there was a net reduction in RE (expressed per gram of lung tissue) between P4 and P8. Part of this reduction was due to growth, as the average body weight increased from 9.0 to 16.5 g during this interval. After the last treatment with VARA or vitamin A on P3, when evaluated on P8, lung RE fell by 82% in the VARA group, and by 50% in the vitamin A group. However, despite this reduction, the lung RE concentration on P8 was still sig-
nificantly greater in neonates previously treated with VARA (VARA > vitamin A > control, p < 0.01).

**Dex Reduces Growth, but Does Not Antagonize the Lung RE Response to VARA**

To determine if VARA is effective in increasing lung RE during co-treatment with Dex, neonates received either oil (control) or VARA, both without and with Dex, on P5–7. Table 1 shows growth during and following treatment with Dex, and lung histology parameters measured on P14, seven days after the last treatments with Dex and VARA. During treatment, Dex reduced growth by approximately 30%, as expected from several previous reports [38, 46–48]. The slowing of growth by Dex was significant within the first day of treatment (p < 0.01, data not shown). None of the treatments resulted in significant lung injury (mean hemorrhage score was <0.5, and epithelial injury score was <0.7, on a scale of 0–5, for all groups). Tissue density was lower in the Dex–VARA group than the Dex only group. Radial alveolar counts did not differ by treatment.

Lung RE was significantly increased in neonates treated with VARA alone (p < 0.0001). Co-treatment with Dex did not affect the response to VARA (fig. 2A), and Dex alone had no significant effect on lung RE as compared to the control group without Dex.

Table 1. Growth characteristics and lung morphometry in neonatal rats treated on P5–P7 with Dex, VARA, and the combination

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Dex</th>
<th>VARA</th>
<th>Dex/VARA</th>
<th>ANOVA p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth during treatment (P5–P8), g</td>
<td>4.6 ± 0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.8 ± 0.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.0 ± 0.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Body weight (P14), g</td>
<td>13.9 ± 0.2</td>
<td>13.5 ± 1.6</td>
<td>13.9 ± 1.4</td>
<td>15.0 ± 1.2</td>
<td>0.95</td>
</tr>
<tr>
<td>Tissue density, % of area occupied</td>
<td>29.0 ± 5.6&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>35.5 ± 2.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>31.8 ± 4.0&lt;sup&gt;b&lt;/sup&gt;</td>
<td>26.5 ± 4.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.066</td>
</tr>
<tr>
<td>Radial alveolar counts, number of septae</td>
<td>5.6 ± 1.2</td>
<td>5.4 ± 0.4</td>
<td>5.9 ± 1.2</td>
<td>4.6 ± 0.6</td>
<td>0.25</td>
</tr>
</tbody>
</table>

Lungs were perfusion-fixed and examined on day P14. Mean ± SD (n = 4/group).
<sup>a,b</sup> The mean of the group marked ‘a’ is greater than that of the group marked ‘b’. p < 0.001 by least squares means test.

![Fig. 2.](image_url)
VARA significantly increased liver RE (p < 0.01). Concomitant treatment with Dex did not affect the response to VARA (fig. 2B), while Dex alone caused a slight increase, compared to the control group.

Plasma total retinol (fig. 2C), determined on P8, was somewhat higher in VARA-treated neonates (p < 0.0001), although values in all groups were still in the normal range for rats. Plasma retinol was moderately but not significantly reduced by Dex; however, Dex did not alter plasma retinol response to VARA.

Discussion

Vitamin A in the Newborn Period – Rationale

Several epidemiological and clinical studies have shown that a nutritional deficiency of vitamin A impairs the response to infectious diseases and increases the risk of mortality [for review, see 49, 50], whereas vitamin A supplementation has successfully reduced child mortality in populations at risk of vitamin A deficiency [51]. Mortality was reduced by 64 and 22% in Indonesian and Indian newborns, respectively, who received 50,000 IU of vitamin A (equal to 15 mg retinol) immediately after birth [35, 36]. Strategies to improve vitamin A status in the postnatal period are also of clinical interest as vitamin A has been shown to improve the clinical outcome of extremely low birth weight infants hospitalized for treatment of respiratory distress syndrome [7]. In such settings, hospitalized infants often receive multiple treatments, such as corticosteroids or supplemental oxygen, and therefore it is important to understand the interaction of vitamin A with these treatments.

VARA Increases Lung RE in Newborn Rats More Effectively than Vitamin A

In the present studies we tested a novel preparation, VARA, which is a nutrient-metabolite combination of vitamin A and RA at a 10:1 ratio, for its ability to increase the RE contents of the lungs of newborn rats. VARA, compared to a standard dose of vitamin A, was more effective in newborn rats treated on P1–P3, as lung RE on P4 was nearly 8-fold higher in VARA than in vitamin A neonates. In this period the lungs of newborn rats are in the saccular stage of lung development, similar to that of 24–38 weeks gestational age in humans [30]. The robust increase in lung RE in VARA-treated neonatal rats suggests that this combination dose might be effective in selectively increasing the uptake of retinol into the lungs of premature infants. Because VARA and vitamin A both increased liver RE, and liver vitamin A storage is widely considered as the best indicator, or ‘gold standard’, of whole-body vitamin A status [52, 53], these treatments should be equally effective in improving the overall vitamin A status in neonates, and both would be expected to protect the neonate against the development of vitamin A deficiency. After the last treatment of newborn rats with VARA on P3, the lung RE concentration declined, indicating that newly deposited lung RE can be mobilized. Despite this reduction, RE was still >2 fold higher on P8 in VARA versus vitamin A neonates. The continued elevation of RE after treatment suggests that it might be possible to provide VARA at less frequent intervals and still maintain elevated tissue reserves over several days or longer. Tissue RE storage is essential for the functions of vitamin A because RE is the major form of vitamin A in most tissues and is readily mobilized through hydrolysis to retinol, the immediate substrate for oxidation to retinal acid and RA, the two principal active metabolites of vitamin A [for review see, 22, 54]. It will be important in the future to determine the biochemical fate of VARA-induced lung RE stores, and to understand whether increasing lung RE contents early in life, as in our newborn rat study, has any physiological benefit regarding postnatal lung maturation.

VARA Is Not Antagonized by Dex

Our second study showed that VARA, when given concurrently with Dex, was still effective in increasing lung RE storage. Dex was observed to reduce growth during the period in which it was administered (P5–P7), but body weights on P14 were not different. While previous studies with longer courses of glucocorticoids have shown detrimental effects on alveolarization [31, 32], neonatal rats treated with a short course of VARA, Dex or both combined showed no unusual changes in several indicators of lung injury in our study. These findings in the neonatal rat model may be clinically relevant, especially as neonatologists currently avoid prolonged courses and prefer much shorter courses of steroids.

It has previously been reported that Dex depletes the lungs and liver of vitamin A in vitamin-A-adequate (non-supplemented) neonatal rats [55]. However, Dex did not antagonize the effect of VARA given as an oral supplement. It is possible that the marked increase in RE due to VARA overwhelmed a smaller reduction in RE due to Dex. In most previous studies of Dex-treated postnatal rats, Dex has been administered for a longer time, e.g., P3–P13, and reduced alveolarization has been documented [38, 46, 47]. However, treatment with RA after cessa-
tion of Dex partially rescued septation by increasing the number of alveoli in postnatal rats [56]. Srinivasan et al. [57] reported that Dex decreased and all-trans-RA increased lung alveolar formation in P4–P13 rats, but RA did not prevent Dex-induced changes in lung function. Thus, the interactions of retinoids and Dex are complex, including the effects of Dex on the concentrations of nuclear retinoid receptors [46] and cellular retinoid-binding proteins [33]. The effects of both retinoids and Dex are likely to depend on the time during development in which they are administered. Now that the present study has shown that Dex does not abrogate the effect of V ARA in augmenting lung RE formation, it will be worthwhile to conduct a more detailed study of Dex + V ARA-treated neonates to determine if V ARA helps to ameliorate Dex-induced lung injury during treatment and in the period of catch-up growth.

Conclusions

VARA increased lung RE content 8-fold more effectively than vitamin A in newborn and 1-week-old neonatal rats, and the increase in lung RE due to V ARA was not attenuated by Dex. This novel nutrient-metabolite combination may be useful and potentially more effective than vitamin A alone in delivering retinol to the lungs in the perinatal period. The effectiveness of VARA in increasing RE in newborn rat lungs in the late saccular stage suggests that VARA may have potential in premature infants, while the effectiveness of VARA in the presence of Dex suggests that co-treatment with glucocorticoid therapy would not interfere with the accumulation of RE in the lungs. Further studies of the physiological effects of VARA in neonates are warranted. The synergistic effect of vitamin A and retinoic acid that we have demonstrated in the newborn rat model is of possible therapeutic significance. Pilot clinical trials are needed to determine optimal dosage, followed by a larger multi-center randomized controlled trial to prove efficacy in reducing BPD in the human preterm neonate.

Acknowledgement

This work was supported in part by NIH R01 CA-90214 (A.C.R.), K08 HD-046513 (N.A.), C06 RR 15490 (N.A.), and funding from the Children's Center Research Initiative (N.A.) and Dorothy Foehr Huck funds (A.C.R.). The authors are grateful to Dr. Nan-qian Li for assistance with tissue analysis.

References
